Stemtech Launches "StemPets(TM)" - the All-Natural Longevity Nutraceuticals Developed for Pets
Stemtech Corporation (OTCQB:STEK) has announced the launch of StemPets™, a revolutionary pet nutraceutical supplement, available in the U.S. starting June 2025 and in Mexico two weeks later. The product, designed for dogs and cats, is a 100% plant-based anti-aging and longevity formula featuring anacardic acid as its key ingredient.
The company holds exclusive distribution rights for this AAFCO-registered compound. StemPets™ aims to provide benefits including increased energy levels, shinier coat, healthier skin, better digestion, and improved joint health. This launch represents Stemtech's strategic entry into the pet wellness market, which is projected to exceed $500 billion globally by 2030.
Stemtech Corporation (OTCQB:STEK) ha annunciato il lancio di StemPets™, un innovativo integratore nutraceutico per animali domestici, disponibile negli Stati Uniti a partire da giugno 2025 e in Messico due settimane dopo. Il prodotto, pensato per cani e gatti, è una formula anti-invecchiamento e di longevità al 100% a base vegetale, con acido anacardico come ingrediente principale.
L'azienda detiene i diritti esclusivi di distribuzione per questo composto registrato AAFCO. StemPets™ mira a offrire benefici come un aumento dei livelli di energia, un pelo più lucido, una pelle più sana, una migliore digestione e una salute articolare migliorata. Questo lancio rappresenta l'ingresso strategico di Stemtech nel mercato del benessere degli animali domestici, previsto superare i 500 miliardi di dollari a livello globale entro il 2030.
Stemtech Corporation (OTCQB:STEK) ha anunciado el lanzamiento de StemPets™, un suplemento nutracéutico revolucionario para mascotas, disponible en Estados Unidos a partir de junio de 2025 y en México dos semanas después. El producto, diseñado para perros y gatos, es una fórmula anti-envejecimiento y de longevidad 100% a base de plantas, con ácido anacárdico como ingrediente clave.
La compañía posee los derechos exclusivos de distribución para este compuesto registrado por AAFCO. StemPets™ busca proporcionar beneficios como mayor nivel de energía, pelaje más brillante, piel más saludable, mejor digestión y salud articular mejorada. Este lanzamiento representa la entrada estratégica de Stemtech en el mercado del bienestar para mascotas, que se proyecta superará los 500 mil millones de dólares a nivel global para 2030.
Stemtech Corporation (OTCQB:STEK)는 혁신적인 반려동물 영양보조제 StemPets™를 2025년 6월부터 미국에서, 그리고 2주 후 멕시코에서 출시한다고 발표했습니다. 이 제품은 개와 고양이를 위해 설계된 100% 식물성 항노화 및 장수 포뮬러로, 주요 성분은 아나카르딕 산입니다.
회사는 이 AAFCO 등록 화합물에 대한 독점 유통권을 보유하고 있습니다. StemPets™는 에너지 수준 증가, 윤기 나는 털, 건강한 피부, 소화 개선, 관절 건강 증진 등 다양한 혜택을 제공하는 것을 목표로 합니다. 이번 출시는 2030년까지 전 세계적으로 5000억 달러를 초과할 것으로 예상되는 반려동물 웰니스 시장에 Stemtech가 전략적으로 진입하는 의미를 갖습니다.
Stemtech Corporation (OTCQB:STEK) a annoncé le lancement de StemPets™, un complément nutraceutique révolutionnaire pour animaux de compagnie, disponible aux États-Unis à partir de juin 2025, puis au Mexique deux semaines plus tard. Ce produit, conçu pour les chiens et les chats, est une formule anti-âge et de longévité 100 % à base de plantes, avec de l'acide anacardique comme ingrédient principal.
L'entreprise détient les droits exclusifs de distribution pour ce composé enregistré auprès de l'AAFCO. StemPets™ vise à offrir des bénéfices tels qu'une augmentation de l'énergie, un pelage plus brillant, une peau plus saine, une meilleure digestion et une santé articulaire améliorée. Ce lancement représente l'entrée stratégique de Stemtech sur le marché du bien-être animalier, qui devrait dépasser 500 milliards de dollars à l'échelle mondiale d'ici 2030.
Stemtech Corporation (OTCQB:STEK) hat die Markteinführung von StemPets™ bekannt gegeben, einem revolutionären nutraceutical Ergänzungsmittel für Haustiere, das ab Juni 2025 in den USA und zwei Wochen später in Mexiko erhältlich sein wird. Das Produkt, entwickelt für Hunde und Katzen, ist eine 100 % pflanzliche Anti-Aging- und Langlebigkeitsformel mit Anacardsäure als Hauptbestandteil.
Das Unternehmen besitzt die exklusiven Vertriebsrechte für diese AAFCO-registrierte Verbindung. StemPets™ soll Vorteile wie gesteigerte Energie, glänzenderes Fell, gesündere Haut, bessere Verdauung und verbesserte Gelenkgesundheit bieten. Diese Markteinführung markiert den strategischen Einstieg von Stemtech in den Markt für Haustier-Wellness, der bis 2030 voraussichtlich über 500 Milliarden US-Dollar weltweit erreichen wird.
- Entry into the fast-growing pet wellness market projected to reach $500B by 2030
- Exclusive distribution rights for the key ingredient anacardic acid
- Expansion into high-margin pet supplement sector
- Product leverages existing expertise and distribution channels
- None.
Now Available for purchase in the U.S. Starting June 2025; Launching in Mexico Two Weeks Later
NAPLES, FL / ACCESS Newswire / May 28, 2025 / Stemtech Corporation (OTCQB:STEK), the global leader in Human stem cell nutrition science and nutraceutical innovation, proudly announces the launch of StemPets™, Our newest breakthrough product designed exclusively for pets. Commencing June 2025, pet owners in the United States will be able to order this revolutionary new supplement, with availability in Mexico launching shortly after.
Made with
Built on nearly two decades of innovation and success with human products like StemRelease3™, StemFlo® Advanced, and MigraStem®, StemPets™ represents the company's natural expansion into the booming pet wellness market.
A Multi-Billion Dollar Opportunity
The overall pet care industry is projected to surpass
"StemPets™ taps into currently one of the most explosive growth sectors in health and wellness," added Meyer. "As more consumers prioritize longevity for themselves, it's only natural they want the same for their family pets."
The star ingredient in StemPets™ is "anacardic acid", a powerful all-natural compound registered with the Association of American Feed Control Officials (AAFCO). Stemtech holds exclusive distribution rights with its supplier, ensuring a competitive edge and unmatched quality in this category.
StemPets™ is more than just a new product - it's a gateway into a high-margin, fast-scaling sector. With pet families seeking preventative, natural solutions for pet health, Stemtech is positioned as a first mover in the pet longevity and stem cell supplement sector.
StemPets™ expands not just the product line, but the company's revenue potential. With international availability, a loyal customer base, and unmatched expertise in cellular health, Stemtech is building momentum across two powerhouse industries-anti-aging and pet care.
*( Cats, dogs or any animal)
ABOUT STEMTECH CORPORATION
Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral, skin care and soon pet health products, to increase sales in the wellness industry.
Stemtech's comprehensive product portfolio reflects its dedication to optimal health. Our all-natural innovations like stemrelease3™ (release of the adult stem cells from the bone marrow), StemFlo™ Advanced (circulation of the stem cells through the bloodstream), MigraStem® (migration from the blood stream into the area need support), and OraStem® Toothpaste (whitening teeth, freshening breath, anti-microbial, promoting good gum health) demonstrate the company's unwavering commitment to quality-of-life products and natural effectiveness. The recent launch of Cellect One® Shield: HOCL-a multipurpose mist for skin care, cleaning, and disinfecting-and its integration with the Cellect One® Rapid Renew Stem Cell Peptide Night Cream (featuring the patented QXP ingredient) underscore Stemtech's innovative edge in the beauty, health and wellness industry.
Stemtech is set to break new ground with the June 2025 debut of StemPets™ - a nutritional supplement designed for both dogs and cats. Tapping into the booming global pet wellness market, currently valued at over
For nearly 20 years, Stemtech has not only championed the benefits of natural, plant-based ingredients but has also led the way in scientific innovation within the wellness, anti-aging, and longevity sectors. As industry forecasts and studies from reputable sources like the Global Wellness Institute project unprecedented growth, Stemtech's unwavering commitment to quality and innovation ensures that they will remain at the forefront of this transformative journey-making everyone healthier, while slowing down the aging process naturally.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as "believes," "will," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Stemtech Corporation disseminated by the Company and bearing its name are considered official.
For Investor Relations Information Contact:
CEO Charles S. Arnold
Phone: 336-918-0507
Email: callcharlesarnold@gmail.com
Stemtech Corporation
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com
References:
Allied Market Research, "Pet Supplements Market Size, Share & Trends Analysis Report by Pet Type, Application - Global Forecast 2023-2032"
Morgan Stanley Research, "Pet Industry Outlook: How the
SOURCE: Stemtech Corporation
View the original press release on ACCESS Newswire
FAQ
When will Stemtech's StemPets (STEK) be available for purchase?
What are the main benefits of Stemtech's StemPets supplement?
What is the key ingredient in STEK's StemPets supplement?
How does StemPets fit into Stemtech's (STEK) business strategy?
